Blokurima
We represented the owners of Onapharm in the sale of the Blokurima product line, well known in the market for urological health products. Our goal was to find a partner that would enable the brand to grow further and expand internationally.
Náš úkol
Patria was the exclusive sales consultant to conduct a private placement process with a small group of interested pharmaceutical companies.
Patria executed the preparation and coordination of due diligence and negotiation of the transaction documentation, including the commercial terms of the transition period.
The focus of the sales process was to maintain the high reputation of the Blokurima brand in the Czech and Slovak markets as a leader among supplements for the suppression and prevention of urinary tract inflammation symptoms.
A specific feature of this transaction was the buyer's requirement to purchase only selected assets of the company, which required the preparation of a detailed inventory management and production ordering plan during the transition period.
Výsledek
The combination of the high quality of the offer and the reputation of the Zentiva Group was judged to best meet the sellers' objectives, leading to a successful settlement of the transaction within 6 months.
Onapharm Blokurima
Onapharm is a Czech manufacturer of dietary supplements with a focus on supplements for urinary tract and genital problems. The Blokurima product line is the absolute market leader in the Czech Republic and Slovakia for supplements for symptom control and prevention of urinary tract inflammation.
Zentiva Group
Zentiva is a leading pharmaceutical company in Central and Eastern Europe, focusing on the development, production and distribution of generic and OTC medicines and dietary supplements. Zentiva is a portfolio company of the US investment group Advent International.